The 2 analysts offering 12-month price forecasts for Acer Therapeutics Inc have a median target of 10.00, with a high estimate of 10.00 and a low estimate of 10.00. The median estimate represents a +298.41% increase from the last price of 2.51.
The current consensus among 4 polled investment analysts is to Buy stock in Acer Therapeutics Inc. This rating has held steady since August, when it was upgraded from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.46
Reporting Date Nov 17
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.